KimAntony
Posted - 6 days ago
$CRL downgraded to underperform this morning with the PT reduced to $164 - https://www.streetinsider.com/rating_history.php?q=crl
joaquin207
Posted - 1 week ago
$CRL who ever spoke at the conference the other day wasn't real engaged and didn't turn the questions into a platform of company direction. Maybe next week.
IN0V8
Posted - 2 weeks ago
$CRL Morgan Stanley raises PT to $225 from $215
IN0V8
Posted - 2 weeks ago
$CRL Baird raises PT to $211 from $190 JP Morgan ups PT to $215 from $195
StockElementCorporation
Posted - 2 weeks ago
Premarket movers 📈
$SONN +30% (announces Issuance of U.S. Patent covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates, effective until June 2044) $RVLV +21% $QLYS +19% $TMCI +16% $CRL +14% GMED +14% MRCY +13% LDI +12% MGNX +12% CVS +9.0% PGY +7.8% (raises $1B across two new personal loan and auto ABS deals) WSC +7.0% (reportedly activist Toms has built a stake and will push for a strategic review) PRGO +6.5% RYAM +6.3% VERX +5.7% GO +5.6% EXAS -22%
OpenOutcrier
Posted - 2 weeks ago
$CRL (+10.6% pre) Charles River Laboratories Announces Third-Quarter 2024 Results https://ooc.bz/l/47024
DonCorleone77
Posted - 2 weeks ago
$CRL Charles River raises FY24 EPS view to $10.10-$10.30 from $9.90-$10.20 Consensus $10.00. Raises FY24 revenue view to down 2%-3% from down 2.5%-4.5%. The company said, "The Company is updating its financial guidance for 2024, which was previously revised on August 7, 2024. Revenue and non-GAAP earnings per share guidance have been narrowed and slightly raised from the midpoint of the previous ranges to principally reflect the third-quarter financial performance, which exceeded the Company's prior outlook. In addition, GAAP earnings per share guidance has been reduced due primarily to increased charges related to the Company's additional restructuring actions."
DonCorleone77
Posted - 2 weeks ago
$CRL Charles River reports Q3 adjusted EPS $2.59, consensus $2.43 Reports Q3 revenue $1.01B, consensus $976.01M. James Foster, chair, president and CEO, said, "Forward-looking demand indicators were relatively stable in the third quarter, contributing to third-quarter financial performance which exceeded our prior outlook. We are continuing to navigate through a challenging period as global biopharmaceutical clients reduce spending in conjunction with major restructuring and pipeline reprioritization activities, but overall demand trends do not appear to have deteriorated further. In addition, biotech funding has improved in 2024, and demand appears to be demonstrating early signs of stabilization. These factors resulted in a slight, sequential improvement in net book-to-bill and the cancellation rate in the Safety Assessment business."
ChessGM
Posted - 2 weeks ago
$CRL Heads up alert! Only one day until Upcoming earnings on Wednesday, 11/6/2024 for $CRL Bullish (8.2) Charles River Laboratories (CRL) is positioned favorably as it approaches its third-quarter earnings release, with a consensus expectation indicating it is likely to exceed prior earnings estimates. Analysts are optimistic, noting the company's strong history of earnings surprises and the positive momentum from various segments, particularly within its Manufacturing segment. Key financial metrics reveal that CRL's price-to-earnings (P/E) ratio stands at approximately 25.4, which is competitive within the biotech sector where the average P/E is around 30. The company has demonstrated robust earnings per share (EPS) growth, with projections suggesting a growth rate of nearly 10% year-over-year, which is commendable compared to its peers. Revenue forecasts for Q3 2024 suggest a growth trajectory fueled by recent innovations, including the launch of the Retrogenix Non-Human Protein Library, which is expected to enhance the company's service offerings and attract new clients. Additionally, CRL's strategic partnerships, such as the collaboration with Lundbeck leveraging AI technology, further bolster its growth narrative and market position. Looking ahead to the upcoming earnings report, expectations are high, with analysts projecting an earnings per share of $2.15, representing an increase from previous quarters. Historically, CRL has a track record of beating earnings estimates, which adds an additional layer of confidence for investors. The consensus among analysts remains optimistic, with a significant majority recommending a buy or hold position on the stock. The anticipated performance could lead to a potential upward revision in stock price, driven by the strong fundamentals and positive operational developments that CRL has been implementing, positioning it well for sustained growth. - Funds were net buyers of $CRL during the previous reporting quarter. - Top 5 funds with large holdings in $CRL: * Southpoint Capital Advisors LP $238MM. CGMFundRank: 83%, Fund Website: www.southpointcapital.com * Riverbridge Partners LLC $60MM. CGMFundRank: 63%, Fund Website: www.riverbridge.com * American Capital Management Inc $38MM. CGMFundRank: 81%, Fund Website: www.americancapitalmanagement.com * Armistice Capital LLC $25MM. CGMFundRank: 81%, Fund Website: www.armisticecapital.com * Lakewood Capital Management LP $23MM. CGMFundRank: 82%, Fund Website: www.lakewoodcap.com - Last 10 days performance: 0% - Last 30 days performance: -4% - Last 90 days performance: -9% Follow ChessGM on stocktwits.com to get timely earnings alerts. Not a financial advice. Not a trading signal.
ChessGM
Posted - 2 weeks ago
$CRL Heads up alert! Only two days until Upcoming Earnings on Wednesday, 11/6/2024 Bullish (7.5) In evaluating Charles River Laboratories (CRL), the recent developments suggest a robust outlook for the company. As of the latest reports, CRL is anticipated to surpass earnings estimates, reflecting a strong operational performance. Analysts highlight CRL's impressive history of earnings surprises, signaling confidence in the company's capability to deliver positive results. The Manufacturing segment is projected to contribute positively to Q3 revenues, although there may be headwinds from decreased biopharmaceutical demand. Key financial metrics indicate that CRL's P/E ratio stands at approximately 29.5, which is relatively high compared to industry peers, but this is often justified by its strong growth trajectory. EPS growth has been consistently above the industry average, supporting a favorable revenue forecast that anticipates continued expansion in their service offerings. Furthermore, recent partnerships, such as the collaboration with Lundbeck on neurological drug research, and the launch of new therapeutic libraries, enhance CRL's competitive edge and drive innovation in their pipeline. Regarding upcoming earnings reports, CRL is scheduled to announce its Q3 2024 results soon. Analysts are optimistic, with consensus estimates predicting an earnings per share (EPS) increase of around 15% year-over-year. Historically, CRL has displayed a pattern of exceeding EPS expectations, which bodes well for investor sentiment. The company’s earnings release will be pivotal, as it will provide insights into revenue performance across its segments, particularly the Manufacturing and Discovery divisions. Should the earnings report reflect the anticipated growth and validate analyst expectations, it could have a positive impact on the stock price, reinforcing CRL's position as a leader in the biotechnology sector. Consequently, investors should remain attentive to the earnings call for further guidance on future growth prospects and strategic initiatives. - Funds were net buyers of $CRL during the previous reporting quarter. - Top 5 funds with large holdings in $CRL: * Southpoint Capital Advisors LP $238MM. CGMRank: 83% * Riverbridge Partners LLC $60MM. CGMRank: 63% * American Capital Management Inc $38MM. CGMRank: 81% * Armistice Capital LLC $25MM. CGMRank: 81% * Lakewood Capital Management LP $23MM. CGMRank: 82% - Last 10 days performance: -4% - Last 30 days performance: -7% - Last 90 days performance: -24% Follow ChessGM! Make your move and get timely earnings alerts from ChessGM. Not a financial advice.
QuantInsider
Posted - 3 weeks ago
Noticing some intriguing activity with $CRL today. The jump in options volume from institutional players is hard to ignore—definitely above the usual levels. InsiderFinance has pointed out that these kinds of shifts can sometimes hint at bigger moves ahead. So, what’s everyone thinking? Is this a sign of something brewing, or are we just reading too much into the noise?
theflynews
Posted - 10/29/24
What You Missed On Wall Street On Tuesday - $CRL - https://thefly.com/permalinks/entry.php/CRLid4007849
Stocksrunner
Posted - 4 weeks ago
$ABBV $CRL $CRM $HAL $LULU are buzzing with unusual options activity, hinting at potential market moves. https://stocksrunner.com/posts/1298
swingingtech
Posted - 1 month ago
$CRL
https://wallstreetwaves.com/clsa-starts-coverage-on-charles-river-laboratories-crl-with-a-cautionary-underperform-rating/
WeeklyTrader
Posted - 1 month ago
Climbing higher with $CRL! RSI: 36.79% 50-day MA: $196.99 200-day MA: $221.56
WeeklyTrader
Posted - 1 month ago
Let’s go, $CRL is about to pop! RSI: 46.18% 50-day MA: $198.73 200-day MA: $222.63
WeeklyTrader
Posted - 1 month ago
In the red for $CRL! RSI: 45.9% 50-day MA: $199.54 200-day MA: $222.86
erevnon
Posted - 1 month ago
Evercore ISI Group downgrades Charles River $CRL from Outperform to In-Line and lowers the price target from $225 to https://marketsblock.com/stock-upgrades-and-downgrades/
themacromindset
Posted - 1 month ago
$CRL Charles River and Lundbeck Enter Agreement Utilizing AI-Powered Logica® to Advance the Discovery of Novel Drugs for Neurological Disease $CRL
erevnon
Posted - 1 month ago
Citigroup downgrades Charles River $CRL from Neutral to Sell and lowers the price target from $215 to https://marketsblock.com/stock-upgrades-and-downgrades/
Stock_Titan
Posted - 2 months ago
$CRL Charles River Laboratories and CEBINA Announce Strategic Collaboration to Accelerate Cutting Edge Neuroscience Research
https://www.stocktitan.net/news/CRL/charles-river-laboratories-and-cebina-announce-strategic-cqy29hhilk1t.html
idkmikes57
Posted - 2 months ago
$CRL what happened!
Thestocktraderhubzee
Posted - 2 months ago
$CRL Charles River Laboratories And Insightec Announce Five-Year Strategic Collaboration To Leverage Focused Ultrasound Technology For Drug Discovery And Preclinical Development In Neuroscience, Aiming To Improve Efficacy Of Neurological Therapies
Stock_Titan
Posted - 2 months ago
$CRL Charles River and Insightec Announce Strategic Collaboration to Advance Therapeutic Development Utilizing Focused Ultrasound in Neuroscience
https://www.stocktitan.net/news/CRL/charles-river-and-insightec-announce-strategic-collaboration-to-b4k18u3gx0v5.html
StockInvest_us
Posted - 3 months ago
Signal alert: $CRL - Oversold Trend Short (Undervalued) https://stockinvest.us/l/do1NEmPK2n
idkmikes57
Posted - 3 months ago
$CRL yeah I'm checking out I can't stand the bleeding good luck!
erevnon
Posted - 3 months ago
TD Cowen maintains Charles River $CRL at Hold and lowers the price target from $228 to https://marketsblock.com/stock-upgrades-and-downgrades/
thinkandpick
Posted - 3 months ago
$CRL $XBI $IBB $LABU $XLV Healthcare and biotech. Charles River Laboratories (CRL): Q2, Cost Structure Streamlining (Rating Upgrade), good SA article: https://seekingalpha.com/article/4713176-charles-river-laboratories-q2-cost-structure-streamlining-crl-stock
Thestocktraderhubzee
Posted - 3 months ago
WATCHLIST AUG 09 2024..
$ARM Daiwa Capital Upgrades ARM Holdings to Outperform, Announces $130 Price Target
$EDIT Barclays Maintains Equal-Weight on Editas Medicine, Lowers Price Target to $7
$ZIP Barclays Maintains Overweight on ZipRecruiter, Lowers Price Target to $10
$ACM Barclays Maintains Overweight on AECOM, Raises Price Target to $105
$CRL Barclays Maintains Equal-Weight on Charles River, Lowers Price Target to $210
